HomeNDC LookupRxCUI directory › RxCUI 2123191

{2 (1.17 ML romosozumab-aqqg 89.7 MG/ML Prefilled Syringe [Evenity]) } Pack [Evenity 210 M... — RxCUI 2123191

RxNorm drug concept · Brand name pack
RxCUI 2123191 Brand name pack · BPCK ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2123191
Official name{2 (1.17 ML romosozumab-aqqg 89.7 MG/ML Prefilled Syringe [Evenity]) } Pack [Evenity 210 MG Dose]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asEvenity 210 MG Dose Pack (2 count)
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)14,773 prescriptions · 47 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Romosozumab-aqqg Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Evenity works in a unique way — it actually helps your body build new bone, not just slow down bone loss. It does this by blocking a protein called sclerostin, which normally limit...
  • What exactly does Evenity do for my bones?
  • Yes — Evenity's bone-building effect is strongest in the first several months and gradually wanes over the 12-month course. After 12 doses, the anabolic (bone-building) benefit has...
  • Why is the treatment only 12 months? Does it stop working?
📖 Read our full Romosozumab-aqqg Injection guide →

🕸️ Concept Web — How {2 (1.17 ML romosozumab-aqqg 89.7 MG/ML Prefille... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {2 (1.17 ML romosozumab-aqqg 89.7 MG/ML Prefilled Syringe [Evenity]) } Pack [Evenity 210 MG Dose] RxCUI 2123191

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Romosozumab 2123126
    • Romosozumab-aqqg 2123180
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Evenity 2123186
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Romosozumab Prefilled Syringe 2123183
    • Romosozumab-aqqg Prefilled Syringe 2646186
    • Romosozumab Injectable Product 2123182
    • Romosozumab-aqqg Injectable Product 2659502
    • Romosozumab Prefilled Syringe [Evenity] 2123188
    • Romosozumab-aqqg Prefilled Syringe [Evenity] 2657679
    • Evenity Injectable Product 2123189
    • Pack 746839
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • 1.17 ML romosozumab-aqqg 89.7 MG/ML Prefilled Syringe [Evenity] SBD · 2123190
  • Romosozumab-aqqg 89.7 MG/ML [Evenity] SBDC · 2123187
  • Romosozumab Prefilled Syringe [Evenity] SBDF · 2123188
  • Romosozumab-aqqg Prefilled Syringe [Evenity] SBDFP · 2657679
  • Evenity Injectable Product SBDG · 2123189
  • Evenity BN · 2123186

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 2123191 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55513-0509-02 2 SYRINGE, GLASS in 1 CARTON (55513-509-02) / 1.17 mL in 1... Evenity Amgen, Inc 2026-01-09
55513-0880-02 2 SYRINGE in 1 CARTON (55513-880-02) / 1.17 mL in 1 SYRINGE... Evenity Amgen, Inc 2019-04-09
55513-0998-02 2 SYRINGE, GLASS in 1 CARTON (55513-998-02) / 1.17 mL in 1... Evenity Amgen, Inc 2024-07-01
Observed labelers: Amgen, Inc (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J3111 Inj. romosozumab-aqqg 1 mg 2 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.